DOI:
10.1055/s-00034925
Hämostaseologie
LinksClose Window
References
Harrison CN, Vannucchi AM, Platzbecker U. et al.
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Lancet Haematol 2018;
5 (02) e73-e81
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.